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Background: Vascular endothelial growth factor-B (VEGF-B) protects against experimental stroke, but the effect of
stroke on VEGF-B expression is uncertain.
Methods: We examined VEGF-B expression by immunohistochemistry in the ischemic border zone 1–7 days after
middle cerebral artery occlusion in rats.
Results: VEGF-B immunoreactivity in the border zone was increased after middle cerebral artery occlusion and was
associated with neurons and macrophages/microglia, but not astrocytes or endothelial cells.
Conclusions: These findings provide additional evidence for a role of VEGF-B in the endogenous response to
cerebral ischemia.
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Vascular endothelial growth factor (VEGF-A), identified
originally as an angiogenic [1] and vascular permeability
[2] factor, also exhibits direct neurotrophic [3] and
neuroprotective [4] effects. VEGF-A reduces infarct size
in acute experimental stroke [5] and has been implicated
in postischemic brain repair [6]. Several studies have doc-
umented the induction of VEGF-A RNA or protein ex-
pression in ischemic brain [7-15], suggesting that VEGF-A
may participate in the brain’s endogenous response to is-
chemic injury. Induction of VEGF-A is observed hours to
days after the onset of focal brain ischemia, is prominently
associated with the ischemic border zone, and occurs in a
variety of cell types, including neurons, astrocytes, endo-
thelial cells, and macrophages/microglia. Upregulation of
the two principal VEGF-A tyrosine kinase receptors,
VEGFR-1 and VEGFR-2, occurs in concert with VEGF-A
induction [7,9,11-14].
In addition to VEGF-A, several other VEGF family mem-
bers have been described, including VEGF-B, VEGF-C, and
placenta growth factor (PlGF). Of these, a protective effect
in stroke has been shown most clearly for VEGF-B. In
homozygous VEGF-B-knockout mice, permanent occlu-* Correspondence: dgreenberg@buckinstitute.org
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reproduction in any medium, provided the orsion of the middle cerebral artery (MCA) produced larger
infarcts and more severe neurological deficits than in het-
erozygous knockout or wild-type mice, suggesting that
VEGF-B is normally protective against ischemia [16].
Moreover, intracerebral administration of VEGF-B reduced
ischemic cell death after MCA occlusion in both VEGF-B
-knockout and wild-type mice [17].
Induction of both VEGF-C [13,18] and PlGF [19] by
cerebral ischemia has been reported, but the effect on
VEGF-B is controversial. One study found increased
VEGF-B immunoreactivity in the ischemic border zone
24 hr after permanent MCA occlusion in mice [17],
whereas another reported reduced abundance of VEGF-B
protein 24 hr after transient MCA occlusion in rats [20].
To address this inconsistency, we measured VEGF-B pro-
tein expression and its distribution for up to 1 wk after
MCAO in rats.Methods
Animal experiments were approved by local committee
review and conducted according to the National Institutes
of Health guidelines. Male Sprague–Dawley rats (280–
310 g) were anesthetized with 4% isoflurane in 70% N2O
and 30% O2 using a mask. A midline incision was made in
the neck, the right external carotid artery was carefully
exposed and dissected, and a 3–0 monofilament nylon. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the right internal carotid artery to occlude the origin of
right middle cerebral artery (MCA). After 90 minutes of
occlusion, the suture was removed to allow reperfusion,
the external carotid artery was ligated, the wound was
closed, and the rats were allowed to awaken. Rectal tem-
perature was maintained (37.0 ± 0.5°C) with a heating pad
and lamp and blood pressure was monitored.
Rats were re-anesthetized 1, 3 or 7 days after MCA oc-
clusion and perfused through the heart with 4% parafor-
maldehyde in phosphate-buffered saline (PBS, pH 7.4).
Brains were dehydrated in graded ethanol, cleared in xy-
lene, and paraffin-embedded. Seven micrometer-thick
serial coronal sections were cut and mounted on glass
slides, which were dried overnight at 42°C. Sections were
then washed in PBS for 20 min, permeabilized in 0.2%
Triton in Tris-buffered saline for 1 h, blocked using 5%
normal goat serum with 0.2% Triton in Tris-buffered
saline for 1 h, and incubated with primary antibody in
blocking buffer at 4°C overnight. The primary antibodies
used were: rat anti-VEGF-B (1:50, Santa Cruz), rabbit
anti-MAP2 (1:500, Chemicon), rabbit anti-CD11b
(1:200, Abcam), rabbit anti-GFAP (1:1,000, Sigma), and
rabbit anti-von Willebrand factor (vwF) (1:500, Sigma).
For diaminobenzidine (DAB) staining, sections stained
for VEGF-B as above were washed in PBS containingFigure 1 VEGF-B immunoreactivity in cerebral cortex 1–7 days after M
core (bar, 50 μm). Middle row, ischemic border zone (bar, 50 μm). Bottom0.1% Tween 20 for 1 h, incubated with biotinylated anti-
mouse IgG secondary antibody (1:200, Vectastain Elite
ABC, Vector) in blocking buffer for 1 h, and placed in
avidin–peroxidase conjugate (Vector) for 1 h. The horse-
radish peroxidase reaction was detected with 0.05% DAB
and 0.03% H2O2. Processing was stopped with H2O and
sections were imaged using a Nikon E300 epifluores-
cence microscope.
For double-label immunofluorescence staining, sections
stained with the primary antibodies listed above were
washed in PBS containing 0.1% Tween 20 for 1 h, incu-
bated with secondary antibody in blocking buffer for 1 h,
washed in PBS for 1 h, and mounted using Prolong Gold
with DAPI (4',6-diamidino-2-phenylindole, Invitrogen).
Secondary antibodies were Alexa Fluor-conjugated donkey
anti-mouse or anti-rabbit IgG (1:200, Molecular Probes).
Sections were imaged on a laser scanning confocal micro-
scope (LSM 510, Carl Zeiss).
Results
DAB-stained sections through the ischemic hemisphere
of rat brains showed increased VEGF-B immunoreacti-
vity, primarily in the ischemic border zone, at 1, 3, and
7 days after MCAO (Figure 1). This immunoreactivity
was associated with cell bodies of round and polygonal
cells and was more pronounced at 1 and 3 than at 7 days.CAO. Top row, top right corner is in the direction of the ischemic
row, ischemic border zone (bar, 20 μm).
Figure 2 (See legend on next page.)
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Figure 2 VEGF-B (left column, green), cell-type marker (second column from left, red), DAPI (third column from left, blue), and merged
(right column, white arrows) staining of cells in the cerebral cortex ischemic border zone 1 and 7 days after MCAO. Cell-type markers
are (A) MAP2 (neurons), (B) CD11b (macrophages/microglia), (C) GFAP (astrocytes), and (D) vWF (endothelial cells). Colocalization of VEGF-B with
MAP2 and CD11b, but not GFAP or vWF, was detected. Bars, 20 μm.
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7-day postischemic brains to identify cell types asso-
ciated with VEGF-B expression. These sections showed
colocalization of VEGF-B with the neuronal marker
MAP2 and the macrophage/microglial marker CD11b,
but not the astrocytic marker GFAP nor the endothe-
lial cell marker vWF (Figure 2). VEGF-B was detected
in ~50% of MAP2-immunopositive cells in the border
zone.
Discussion
The main finding of this study is that VEGF-B protein is
upregulated in neurons and inflammatory (macrophage/
microglial) cells of the ischemic border zone from 1–7 days
after MCAO in rats. This is in accord with previous find-
ings pertaining to other VEGF family members (VEGF-A
and VEGF-C) and VEGF receptors (VEGFR-1, VEGRR-2
and VEGFR-3) [7-15,18,19]. It is also in agreement with
one prior report of increased VEGF-B expression after
cerebral ischemia [17], but contrasts with another study
indicating that VEGF-B expression declines in this setting
[20]. Methodologic differences that might account for the
discrepancy between this latter study and ours include the
use of different rat strains (Wistar vs. Sprague Dawley),
180- vs. 90-min MCAO, single (24 h) vs. multiple (1, 3
and 7 days) postischemic time points, and analysis of the
whole hemisphere by western blot vs. the ischemic border
zone by immunohistochemistry. The latter is especially
likely to have been a factor because whole-hemisphere
sections include the ischemic core, where protein synthe-
sis is impaired, and cannot resolve regional heterogeneity
of protein expression [21].
Our finding of increased VEGF-B expression in ischemic
brain is consistent with other examples of VEGF-B induc-
tion by neuropathological processes. These include cor-
tical cold injury in rats [22], motor neuron degeneration
in SOD1G93A transgenic mice [23], a cell-culture model of
Parkinson’s disease [24], and type IIB focal cortical dyspla-
sia in humans [25]. VEGF-B deletion exacerbates motor
neuron degeneration [23] and paclitexel-induced sensory
neuronopathy [26] in mice, which resembles our earlier
finding that VEGF-B deletion worsens outcome from ex-
perimental stroke in mice [16], and provides additional
support for a neuroprotective role.
Two questions raised by this study are what couples
cerebral ischemia and VEGF-B induction and how
VEGF-B induction affects the ischemic brain. Regardingthe stimulus to induction, VEGF-B differs from VEGF-A
in that the former does not contain a hypoxia-response
element in the promoter region [27] and is not tran-
scriptionally induced by hypoxia [28]. Consequently,
some other mechanism must be involved in its induction
by ischemia.
How induction of VEGF-B affects outcome from
stroke is unclear, but VEGF-B has been shown to be an
antiapoptotic [17] and cell-survival [29] factor in several
tissues. Unlike VEGF-A, it is not thought to play a
prominent role in angiogenesis [30], and operates pri-
marily via interaction with VEGFR-1, rather than the
angiogenesis-associated VEGFR-2 targeted primarily by
VEGF-A [31]. In the retina, VEGF-B signaling through
VEGFR-1 inhibits proapoptotic gene expression, as well
as retinal ganglion cell death from oxidative injury,
axotomy, and excitotoxicity [17]. Similar mechanisms
might therefore mediate the effects of VEGF-B in stroke.
In addition, VEGF-B stimulates adult neurogenesis [32],
which may promote a more favorable outcome after
stroke [33,34].
Conclusions
VEGF-B, like other VEGF family members, is induced by
experimental stroke, and may therefore contribute to en-
dogenous adaptive mechanisms that limit ischemic brain
injury.
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